Aerodrug

Financial support for an aerosol research program

sandrine — 2010-08-23T07:22:31Z

2010, july Aerodrug has obtained a grant to work about CFD aerosol modeling, in collabration with the French agency for atomic energy, CEA-Le Ripault (Monts, FR). For this occasion, a PhD graduate student has joins Aerodrug for three years to undertake a research focused on the mathematical aerosol modeling applyed to inhalation devices. This research program tightens up the previous collaboration etablished with the CEA-Le ripault. The Region Centre funded a part of this (...) - News

DDL21 conference

sandrine — 2010-08-20T08:12:04Z

2010, December 8-10 "Drug Delivery to the Lungs", the first european conference and exhibition dedicated to pulmonary and nasal drug delivery, is announced to held on December 8-10, 2010, at Edinburgh (Scotland). http://ddl-conference.org.uk/index.php?q=home Aerodrug will be present at Edinburgh for the DDL21 conference We invit you to meet us at the exhibition area, on the stand of the Diffusion Technique Française, (...) - News

In vivo aerosol measurements

sandrine — 2010-04-12T08:56:28Z

In vitro and in vivo scintigraphic studies could be performed using gamma imagers dedicated to a research activity. Gamma camera E-CAM (Siemens) Mini gamma imager for small animal imaging (Biospace) Some examples - Technology

IESRT-2010 conference

sandrine — 2010-04-12T08:56:21Z

2010, December 13-15 The 2010 IESRT meeting, for International Expertise of Selected Rhinologic Topics, organized by Roger Jankowski, will be held for the second time at Nancy, the 13th-15th december. «... the same objective : trying to understand nose and sinus diseases beyond the current consensus and progress in diagnosis and treatment.» Editorial. R. Jankowsky. Aerodrug will attend to the 2010-IERST meeting, the occasion to exchange new ideas and concept, with international expert (...) - News

Development of the NL20® nebulizer

sandrine — 2010-04-12T08:56:19Z

Aerodrug and DTF develops a new nebulizer for all upper airways indications, such as laryngitis or tracheitis : the NL20®. adapted particle sizegood targetting of upper airways pulmonary drug deposition strongly reduce In vitro evaluation The NL20® nebulizer produce an aerosol with a MMAD equal to 10.1µm and with 77% of particles > 5µm. - More details about NL20® aerosol characteristics. In vivo aerosol deposition Two nebulizer were tested in three animal models : a standard jet (...) - Development

The Idehaler®Pocket for Meveol®

sandrine — 2010-04-12T08:56:10Z

2009, September 14 Alaxia, company created in April 2008, develops an anti-inflammatory and anti-bacterial new treatment for cystic fibrosis: Meveol®. Meveol® has been recently granted orphan drug status by both EU Medicinal Agency (EMA) and US Food and Drug Agency (FDA). Alaxia selected the IdehalerPocket® for Meveol® nebulization. The Meveol® in association with the IdehalerPocket® is a new advance for the cystic fibrosis treatment and for the life quality of cystic fibrosis patients. (...) - News

Collaborations

sandrine — 2010-04-12T08:55:45Z

Scientific and industrials partners which collabore or have collaborated with the department "Aerosols" of DTF since 1999, updated "Aerodrug" since december 2008. Academic collaborations Université François Rabelais, Tours, FR INSERM U618 "Protéases et vectorisations pulmonaires", Tours, FR CHRU Bretonneau, Tours, FR INRA-Tours, Nouzilly, FR CEA-Le Ripault, Monts, FR CHU Bellevue, Saint Etienne, FR IFR143, UMR-CNRS 5148, Ecole des Mines, Saint Etienne, FR CHU Croix-Rousse, Lyon, FR ENS (...) - Collaborations

Idehaler-Pocket®

sandrine — 2010-04-12T08:54:09Z

Idehaler-Pocket®, a virtual valve holding chamber Based on dynamic fluid properties, an innovative new vertical holding chamber has been developed for a mesh nebulizer. The Idehaler-Pocket® offers a virtual valve nebulization system. In terms of performance, the Idehaler-Pocket® allows to: increase the inhalable fraction - up to 77%, deliver a 4µm particle size aerosol. The Idehaler-Pocket® offers the advantage to be very small and portable, easy to use. Scientific communication (...) - Development

In vitro aerosol measurements

sandrine — 2010-04-12T08:53:56Z

Particle size measurments Laser diffraction : Mastersizer X and Spraytec (Malvern instruments), Cascad impaction Next Generation Impactor (NGI), model 170, operating at 15 and 30L/min, (MSP corporation), Andersen Cascad Impactor (ACI), series 20-800 Mark II, operating at 28.3 L/min (Thermo Andersen), 10-stage cascade impactor, IMPAQ GS-1, operating at 1L/min (California Measurements), 6-stage cascad impactor, AS-6, operating at 15L/min (California Measurements), 8-stage Marple (...) - Technology

Ring® nebulizer

sandrine — 2010-04-12T08:53:40Z

The Ring®, a new jet nebulizer specially designed for mechanical ventilated patients. Jet-nebulizers for mechanical ventilation offers the advantage to be disposable but significantly modify the ventilation parameters due to their gas-operation. Indeed, the addition of an external air-flow affect pressure curves and conduct to employ these nebulizer with caution. The Ring® nebulizer was designed to adapt and keep efficient and available jet-nebulization for mechanical ventilated (...) - Development